|
|
|
25 Sep 2007 |
MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
|
|
25 Sep 2007 |
Lundbeck in-licenses Circadin(R), a drug approved for the treatment of primary insomnia from Neurim Pharmaceuticals
|
|
25 Sep 2007 |
Verus Pharmaceuticals Announces Divestiture of Pediatric Asthma Development Programs to AstraZeneca
|
|
19 Sep 2007 |
LigoCyte Pharmaceuticals Announces Collaboration With Biogen Idec to Develop Anti-CD103 Therapies
|
|
18 Sep 2007 |
Exclusive Rights to Kuvan(TM) Data Licensed to Asubio Pharma in Japan
|
|
18 Sep 2007 |
A major pharmaceutical company has taken an exclusive option to BA058, a compound licensed by Ipsen to Radius in 2005
|
|
13 Sep 2007 |
Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
|
|
12 Sep 2007 |
Flamel Technologies Announces Medusa® License Agreement with Wyeth Pharmaceuticals
|
|
12 Sep 2007 |
Inhibitex Licenses HIV Integrase Inhibitor Program
|
|
11 Sep 2007 |
GlaxoSmithKline and Sepracor Inc. announce international alliance for commercilisation of Lunivia
|
|
11 Sep 2007 |
Palatin Technologies Announces Reacquisition of Full Rights to Bremelanotide Program
|
|
08 Sep 2007 |
Penwest Enters Into Research and Development Agreement With Otsuka Pharmaceutical
|
|
07 Sep 2007 |
Theravance Retains Full Ownership of Gastrointestinal Motility Dysfunction Program and TD-1792 Antibiotic
|
|
06 Sep 2007 |
Eisai Inc. Enters Copromotion Agreement with Salix Pharmaceuticals, Ltd. for Balsalazide Products
|
|
06 Sep 2007 |
Meda acquires exclusive rights to potential specialty blockbuster product in the US
|
|
06 Sep 2007 |
Lundbeck and Takeda form Alliance to Develop and Commercialize a Portfolio of Novel Compounds in the US and Japan for the Treatment of Mood and Anxiety Disorders
|
|
04 Sep 2007 |
Jerini Regains Commercialization Rights to Icatibant for the Treatment of Hereditary Angioedema in North America
|
|
04 Sep 2007 |
Tibotec Pharmaceuticals Ltd returns MIV-210 licensing rights to Medivir
|
|
31 Aug 2007 |
Anesiva grants specific-use license of its needle-free drug delivery technology to Particle Therapeutics for diabetes drug
|
|
31 Aug 2007 |
Paion's partner Forest terminates co-development on Desmoteplase
|
|
30 Aug 2007 |
Codexis Licenses New Drug Metabolite Profiling and Lead Diversification Technology from The California Institute of Technology
|
|
30 Aug 2007 |
Inflazyme Pharmaceuticals does not Exercise Option with Helicon Therapeutics to PDE4 Inhibitor, IPL455,903, in Learning and Memory Disorders
|
|
29 Aug 2007 |
XOMA Licenses Antibody Technology to Pfizer
|
|
29 Aug 2007 |
MGI PHARMA Signs Agreement for Rights to Novel Treatment for Thrombocytopenia
|
|
28 Aug 2007 |
Medicis and Hyperion Therapeutics Announce Strategic Collaboration
|
|
25 Aug 2007 |
Phylogica enters anti-microbial field
|
|
24 Aug 2007 |
Gene Logic establishes agreement with Merck Serono to discover new development paths for multiple clinical-stage drug candidates
|
|
22 Aug 2007 |
BioMarin licenses technology from leading cystic fibrosis research laboratory at the University of California, San Francisco
|
|
22 Aug 2007 |
Daiichi Sankyo and Forest Laboratories sign Letter of Intent for co-promotion of AZOR(TM)
|
|
22 Aug 2007 |
Abraxis BioScience and The Scripps Research Institute Enter Exclusive Licensing Agreement for the Worldwide Development and Commercialization of a Novel Epothilone Therapeutic for the Treatment of Cancer
|
|
21 Aug 2007 |
Samaritan Licenses Tumor Inhibiting Cancer Drugs That Also Distinguish Cancerous Tumors to Improve On Chemotherapy
|
|
20 Aug 2007 |
Pharmion and MethylGene announce collaboration to develop sirtuin inhibitors as anti-cancer agents
|
|
16 Aug 2007 |
Cell Therapeutics, Inc. (CTI) enters agreement to acquire lymphoma drug Zevalin(R) from Biogen Idec for sales and marketing in the United States
|
|
13 Aug 2007 |
Ophthotech raises $36 million; in-licenses two compounds for macular degeneration
|
|
11 Aug 2007 |
Unigene in-licenses potential therapies for inflammation and cardiovascular disease from University of London
|
|
11 Aug 2007 |
Proteo, Inc./Proteo Biotech AG - Minapharm/Rhein Minapharm Biogenetics SAE: Proteo Biotech, Germany and Minapharm, Egypt enter into development and license agreement for Elafin
|
|
10 Aug 2007 |
Georgetown University and Samaritan sign exclusive licensing agreement for novel treatment of Cushing's syndrome
|
|
09 Aug 2007 |
Protalix BioTherapeutics signs agreement to license acetylcholinestrase development technology
|
|
09 Aug 2007 |
Biovitrum strengthens its relationship with Wyeth
|
|
09 Aug 2007 |
Biomira and Merck KGaA sign amended and restated collaboration and supply agreements related to Stimuvax(R)
|
|
09 Aug 2007 |
Abraxis BioScience Announces Licensing Agreement with Biocon Limited for the Commercialization of ABRAXANE in India
|
|
08 Aug 2007 |
Intellect Neurosciences, Inc. and Medical Research Council Technology (U.K.) Enter into Agreement to Humanize Two Monoclonal Antibodies for the Treatment of Alzheimer's Disease
|
|
07 Aug 2007 |
Bayer HealthCare and Nektar Therapeutics Launch Global Development and Commercialization Agreement to Fight Gram-Negative Pneumonias
|
|
07 Aug 2007 |
CeNeS Licenses New Intravenous Anaesthetic to Ono in Japan
|
|
04 Aug 2007 |
Dyax Corp. Licenses Antibody Phage Display Libraries to Cambridge Antibody Technology
|
|
03 Aug 2007 |
Hana Biosciences Licenses North American Commercial Rights for Zensana(TM) to Par Pharmaceutical in a $50 Million Deal
|
|
03 Aug 2007 |
Genmab regains rights to HuMax-TAC
|
|
03 Aug 2007 |
Santhera and Takeda Extend European Marketing Collaboration for SNT-MC17 into Duchenne Muscular Dystrophy
|
|
02 Aug 2007 |
Takeda to License CCR5 Antagonists for Treatment of HIV Infection to Tobira Therapeutics, Inc.
|
|
28 Jul 2007 |
Eisai Enters into In-licensing Agreement with Sepracor for Eszopiclone Insomnia Treatment
|
| |
|
Results 251 - 300 of 814 |
